Trial Profile
Phase II Study of Everolimus in Children and Adolescents With Refractory or Relapsed Osteosarcoma.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Osteosarcoma
- Focus Therapeutic Use
- 06 Aug 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov.
- 25 Mar 2013 Planned end date changed from 1 Mar 2018 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 24 Jun 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.